Steve Bryson, PhD, science writer —

Single dosing of orally inhaled POL6014, an experimental therapy to treat chronic lung inflammation, can effectively block the activity of a pro-inflammatory enzyme in the lungs of people with cystic fibrosis (CF), results from a Phase 1 clinical trial show. The data were published…

Amikacin liposome inhalation suspension (ALIS) showed the same efficacy and similar safety profile as tobramycin inhalation solution (TIS) for the treatment of cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infection, a comparative clinical study showed. The study, “Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis,” was…

Blocking a pro-inflammatory protein complex, broadly known as the neutrophil inflammasome, represents a new way of treating chronic Pseudomonas aeruginosa infections in cystic fibrosis (CF) patients, a proof-of-concept study demonstrated.  The study, “Specific Inhibition of the…

Clinical centers with high screening rates for cystic fibrosis-related diabetes (CFRD) were more likely to achieve early CFRD diagnosis and prevent lung function decline, a study has found. This was reported in a study, “The association of pediatric cystic fibrosis-related…

Pulmonary infection with a specific species of the Mycobacterium avium complex (MAC), called Mycobacterium intracellulare, can be aggressive in people with cystic fibrosis (CF), with a greater loss of lung function evident but a lesser incidence of a secondary lung infection, a single-site study reports. This species also responded best…

Molecules used by a bacterial species against other microbes, called rhamnolipids, can bolster the ability of a standard antibiotic to penetrate treatment-resistant strains of Staphylococcus aureus by essentially making holes in the membrane of its cells, a new study confirms. The study, “…